刮治法联合重组人干扰素α-2b凝胶治疗扁平疣临床疗效观察

目的观察刮治法联合重组人干扰素α-2b凝胶治疗扁平疣的临床疗效。方法将入选的56例扁平疣患者随机分为治疗组和对照组各28例,治疗组予刮治法联合重组人干扰素α-2b凝胶治疗,对照组仅予重组人干扰素α-2b凝胶外用,共治疗8周,两组患者均每周观察1次皮损变化情况,疗程结束后评价疗效。结果治疗8周后,治疗组痊愈19例(67.86%),显效4例(14.29%),好转3例(10.71%),无效2例(7.14%),有效率为82.14%;对照组痊愈6例(21.43%),显效3例(10.71%),好转4例(14.29%),无效15例(53.57%),有效率为32.14%;两组有效率差异有统计学意义(P<0.05)。结论刮治法联合重组人干扰素α-2b凝胶治疗扁平疣具有较好的疗效。     

皮损内注射α-2b干扰素加中药治疗扁平疣疗效观察

目的:观察皮损内注射干扰素联合中药治疗扁平疣的疗效。方法:扁平疣患者154例分为两组,治疗组78例皮损内注射α-2b干扰素100万u,每周1次,中药煎服每日2次;对照组76例,肌注聚肌胞2 mL、皮下注射转移因子3 mg,每3天1次。结果:治疗组治愈率76.92%,有效率97.44%;对照组分别为34.21%、73.68%。两组有效率比较差异有统计学意义(P<0.01)。结论:皮损内注射干扰素联合中药治疗扁平疣疗效显著。     

中药鸦胆子联合重组人干扰素α-2b凝胶外用治疗扁平疣的疗效观察

目的:观察中药鸦胆子联合重组人干扰素α-2b凝胶外用治疗扁平疣的临床疗效。方法:将86例扁平疣患者随机分为试验组和对照组,每组各43例。试验组采用中药鸦胆子联合重组人干扰素α-2b凝胶外用治疗,对照组仅外用重组人干扰素α-2b凝胶治疗,两组疗程最长均为4周。比较两组疗效。结果:治疗结束后,试验组有效率为72.1%,对照组有效率为34.8%,试验组有效率明显高于对照组,差异有统计学意义(χ^2=11.96,P<0.05)。结论:中药鸦胆子联合重组人干扰素α-2b凝胶外用治疗扁平疣疗效好,安全性高。     

重组人干扰素α-1b注射液联合匹多莫德口服溶液治疗扁平疣疗效观察

目的分析应用重组人干扰素α-1b注射液联合匹多莫德口服溶液治疗扁平疣的临床效果。方法 200例扁平疣患者随机分为实验组和对照组,对照组单纯采用重组人干扰素α-1b注射液治疗,实验组采用重组人干扰素α-1b注射液联合匹多莫德口服溶液治疗,对比分析两组患者的临床治疗效果。结果实验组有效率（96.00%）明显高于对照组（56.00%）,差异有统计学意义（P〈0.05）。结论应用重组人干扰素α-1b注射液联合匹多莫德口服溶液治疗扁平疣的临床效果显著,安全可靠。     

跖疣患者96例封闭治疗疗效观察

目的探讨采用重组人干扰素α-2b100万U局部封闭治疗跖疣的疗效。方法治疗组用重组人干扰素α-2b100万U局部封闭治疗,对照组用重组人干扰素α-2b100万U臀部肌肉注射治疗。结果治疗组有效率为88.0%,对照组为71.6%,两组有效率比较差异有统计学意义(P<0.05)。结论重组人干扰素α-2b局部封闭治疗跖疣疗效好。     

5%咪喹莫特乳膏与重组人干扰素凝胶预防扁平疣冷冻后复发的疗效比较

目的对比液氮冷冻后局部外用5%咪喹莫特乳膏和重组人干扰素α-2b凝胶对预防扁平疣复发的作用。方法将66例扁平疣患者给予液氮冷冻去除肉眼可见的疣体后,随机分两组,治疗组外用5%咪喹莫特乳膏,1次/qod;对照组外用重组人干扰素α-2b凝胶,(3~4)次/d,疗程均为8周,随访3个月,比较两组患者治愈、复发情况及不良反应。结果治疗组和对照组的治愈率分别为90.9%和63.6%。差异具有统计学意义(P0.05)。结论扁平疣液氮冷冻后局部使用5%咪喹莫特乳膏比重组人干扰素α-2b凝胶更阻止扁平疣复发。     

5—氟尿嘧啶皮损内注射联合干扰素治疗多发性跖疣疗效观察

目的观察5—氟尿嘧啶注射液皮损内注射联合重组人干扰素注射液肌注治疗多发性跖疣的治疗效果。方法门诊收治的多发性跖疣患者67例,随机分为治疗组35例,皮损内注射5—氟尿嘧啶注射液;对照组33例,采用电离子汽化祛除疣体;2组患者均同时联合重组人干扰素α-2b注射液肌注治疗。二组患者治疗1月,于治疗后3个月观察疗效。结果治疗组治愈率82.9%,复发率8.6%;对照组治愈率60.6%,复发率39.4%。2组疗效比较P0.05,差异有显著性。结论 5—氟尿嘧啶注射液皮损内注射联合重组人干扰素α-2b注射液肌注治疗多发性跖疣,创伤小,痛苦轻,疗效好。     

重组人干扰素α-2b皮损内注射治疗寻常疣疗效观察

目的 观察干扰素皮损局部注射治疗寻常疣疗效。方法 采用重组人干扰素α-2b注射液100万u加2％利多卡因1ml混合进行寻常疣皮损局部注射。结果 经过1～4次注射后，76例207枚疣体消退178枚，痊愈率为86．0％，有效率为93．2％。结论 干扰素皮损内注射治疗寻常疣，操作较简便，损伤亦较小，患者痛苦小，疗效满意。     

甘露聚糖肽治疗扁平疣的临床疗效观察

目的观察甘露聚糖肽治疗扁平疣的疗效。方法将97例患者随机分为治疗组和对照组。对照组39例,予重组人干扰素α-2b凝胶和他扎罗汀乳膏外用;治疗组58例,在上述外用药物基础上,加用甘露聚糖肽注射液5mg肌注,隔日一次。治疗8周后观察其有效率。结果治疗组痊愈16例,显效19例,好转16例,无效7例,有效率86.2%;对照组痊愈7例,显效11例,好转10例,无效11例,有效率71.8%。两组比较差异有统计学意义(P<0.05)。结论甘露聚糖肽联合重组人干扰素α-2b凝胶和他扎罗汀乳膏外用治疗扁平疣疗效好,优于单纯外用药组,值得临床应用。     

维A酸霜联合重组人干扰素α-2b凝胶治疗扁平疣65例疗效观察

目的：观察维A酸霜联合可重组人干扰素α-2b凝胶治疗扁平疣的疗效。方法：将患行随机的分成两组，治疗组外涂维A酸霜和重组人干扰素α-2b凝胶，对照组外涂维A酸霜，疗程8周。结果：治疗组有效率92．31％，对照组有效率72.55％，两组差异有显著性（P〈0．05）。结论：维A酸霜联合重组人干扰素α-2b凝胶治疗翩平疣效果优于对照组。     

新疆地区皮炎及湿疹患者斑贴试验结果分析

目的：确定新疆地区皮炎及湿疹患者的常见接触性变应原.方法：采用斑贴试验试剂盒对202例患者进行了斑贴试验.结果：202例患者中有122例至少对一种物质过敏,总阳性率为60.40%,阳性率较高的几种变应原依次为硫酸镍39例（19.31%）,白降汞31例（15.35%）和橡胶24例（11.88%）.结论：新疆地区皮炎及湿疹主要变应原为3种化学物质.     

Patch testing is a useful investigation in children with eczema

Background. Allergic contact dermatitis in children is less recognized than in adults. However, recently, allergic contact dermatitis has started to attract more interest as a cause of or contributor to eczema in children, and patch testing has been gaining in recognition as a useful diagnostic tool in this group. Objectives. The aim of this analysis was to investigate the results of patch testing of selected children with eczema of various types (mostly atopic dermatitis) attending the Sheffield Children's Hospital, and to assess potential allergens that might elicit allergic contact dermatitis. Patients and methods. We analysed retrospectively the patch test results in 110 children aged between 2 and 18 years, referred to a contact dermatitis clinic between April 2002 and December 2008. We looked at the percentages of relevant positive reactions in boys and girls, by age groups, and recorded the outcome of treatment following patch testing. Results. One or more positive allergic reactions of current or past relevance was found in 48/110 children (44%; 29 females and 19 males). There were 94 allergy‐positive patch test reactions in 110 patients: 81 had a reaction of current or past relevance, 12 had a reaction of unknown relevance, and 1 had reaction that was a cross‐reaction. The commonest allergens with present or past relevance were medicaments, plant allergens, house dust mite, nickel, Amerchol® L101 (a lanolin derivative), and 2‐bromo‐2‐nitropropane‐1,3‐diol. However, finding a positive allergen was not associated with a better clinical outcome. Conclusions. We have shown that patch testing can identify relevant allergens in 44% of children with eczema. The commonest relevant allergens were medicament allergens, plant allergens, house dust mite, nickel, Amerchol® L101, and 2‐bromo‐2‐nitropropane‐1,3‐diol. Patch testing can be performed in children as young as 2 years with the proper preparation.     

无锡市1065例皮炎湿疹类皮肤病的接触性变应原分析

目的 探讨无锡市皮炎湿疹类皮肤病患者的接触性变应原及其临床意义。 方法 斑贴试剂盒对门诊确诊的1065例皮炎湿疹类皮肤病患者进行斑贴试验,并对结果作统计学处理。 结果 斑贴试验总阳性率83.19%,性别、年龄差异无统计学意义。阳性率居前6位的变应原依次为重铬酸钾、氯化钴、硫酸镍、甲醛、卡巴混合物和芳香混合物。其中重铬酸钾和卡巴混合物的阳性检出率男性显著高于女性,硫酸镍和甲醛的阳性检出率女性显著高于男性,差异有统计学意义（P < 0.01）。氯化钴的阳性检出率中青年组和老年组显著高于儿童组,硫酸镍的阳性检出率中青年组显著高于儿童组,差异有统计学意义（P < 0.05）。结论 重铬酸钾、氯化钴、硫酸镍、甲醛、卡巴混合物和芳香混合物是无锡市引起皮炎湿疹类皮肤病的主要变应原。     

Patch test reaction on Ethiopian subjects with eczema

Background  Allergic contact dermatitis is a common condition with an incidence of 1–10% in the general population. An increasing number of allergens in the environment are responsible for the condition. These allergens can be identified using patch testing. Many countries have a standard series of common allergens used for patch testing. There is no standard series of allergens in Ethiopia, and our objective was to obtain baseline data for common allergens for future standardization.
Methods  One hundred and eighty-one subjects with eczema were patch tested using 17 selected allergens from Chemotechnique Diagnostics AB employing a standard procedure.
Results  Positive patch test reactions were detected in more than 60% of subjects, the most common allergen being nickel, followed by fragrance mix and butylphenolformaldehyde. A higher incidence of positive reactions was seen in females.
Conclusions  A high incidence of positive patch test reactions was identified in the study population, and the introduction of patch testing in Ethiopia is essential for the management of allergic contact dermatitis.     

Updating the British Society for Cutaneous Allergy Facial Series to ensure accurate diagnosis of allergic contact dermatitis

Allergic contact dermatitis (ACD) is a localised form of dermatitis or eczema which occurs 48‐72 hours after a substance which causes allergy (an allergen) has been in contact with the skin. It affects 20% of people. ACD to cosmetics is widely reported, with facial eczema being the main presenting complaint. ACD to cosmetics is diagnosed by patch testing to the British Society of Cutaneous Allergy (BSCA) facial series. Patch testing is a specialist test performed by a dermatologist which involves applying a series of allergens to the patient’s back, which remains in place for 48 hours until they are removed. The patient then returns, 72 hours after the initial application of the allergens, for the final readings to see if they have any positive allergic reactions. To ensure we are accurately diagnosing ACD, patch test series should be continually reviewed to identify relevant and emerging allergens and remove those that are outdated. The BSCA facial series currently recommends 26 allergens and was last modified in 2012. We set out to update the BSCA facial series. We assessed the results from 12 U.K. and Ireland patch test centres’, facial series from January 2016 to December 2017. We recorded the number of allergens tested in each centre and calculated the patch test rate for each allergen, using a 0.3% positive patch test rate as the threshold criterion for inclusion. A total of 4224 patients were patch tested to the BSCA facial series. The number of allergens included in individual centres facial series ranged from 24 to 66 with a total of 103 allergens tested across all centres. Twelve of the 26 allergens in the BSCA facial series had a positive patch test rate of less than 0.3% and 14 had a rate more than 0.3%. Twenty‐five allergens not recommended in the BSCA facial series had a positive patch test rate more than 0.3%. Despite a recommended facial series, there is wide variation in practice amongst patch test centres. Using our results, we have updated the BSCA facial series which now contains 24 allergens. Fifteen allergens remain, 11 allergens have been dropped and nine new allergens have been added. Linked Article:   Rolls et al. Br J Dermatol 2021; 184 :151–155 .     

Environmental contact factors in eczema and the results of patch testing Chinese patients with a modified European standard series of allergens

Environmental contact factors in eczema were investigated in China by clinical questionnaire and patch testing patients with a modified European standard series of allergens. 217 consecutive eczema patients were studied. Contact dermatitis (CD) was clinically diagnosed in 30% of the patients. Among the patients patch tested, 46 patients had clinically diagnosed allergic CD (ACD), 20 patients clinically had non-ACD (NACD) (including 16 cases of irritant contact dermatitis, 1 case of phototoxic contact reaction and 3 cases of asteatotic eczema) and 115 patients had clinically suspected ACD. 45 patients (98%) in the ACD group went on to have relevant patch test results. The most common ACD was from metals, fragrance materials, cosmetics and rubber materials. The most common contact allergens identified were nickel, fragrance mix, para-phenylenediamine (PPD), carba mix and thimerosal. No adverse reactions were observed to patch testing, except for pruritus in patch-test-positive patients. The positive rate of patch testing in ACD was much higher than that in NACD (98% versus 15%, P < 0.05, chi(2)-test). 60 (28%) patients had facial dermatitis (FD). Among these, 20 (33%) were confirmed as having ACD. 48 (22%) patients had hand dermatitis (HD). Among these, 7 (15%) were confirmed as having ACD. Fewer patients were confirmed as having ACD in the HD group than in the FD (15% versus 33%, P < 0.05, chi(2)-test). Although the difference was not significant, the total positivity rate in the HD group (55%) was lower than in the other groups. 65 (30%) patients had unclassified endogenous eczema (UEE). The total positive rate of patch testing in the UEE group (56%) was no different from that in the FD or HD groups. However, the relevance of positive patch tests was hard to determine in UEE. These results indicate that CD is common in eczema; relatively more patients with FD have ACD, while other factors, such as irritation, may play more of a role in HD. The total positive rate of patch testing in the UEE group was no different from that in the FD or HD groups, suggesting that patch testing should be stressed in UEE and the relevance of positive patch test results in UEE should be studied further. It is effective and safe to patch eczema patients with a modified European standard series of allergens in China.     

过敏专科门诊3 051例湿疹皮炎患者血清特异性IgE检测结果分析

目的分析湿疹皮炎患者血清特异性IgE检测结果。方法回顾2021年4月1日至2022年3月31日于华山医院过敏专科门诊就诊的3 051例湿疹皮炎患者, 利用Phadia过敏原检测系统检测患者的血清特异性IgE水平, 计算各项过敏原的检测阳性率, 分析湿疹皮炎患者的常见吸入性过敏原和食物过敏原。计数资料组间比较采用χ2检验。结果 3 051例湿疹皮炎患者中, 特应性皮炎1 412例, 其他湿疹/皮炎1 639例。1 629例(53%)过敏原阳性, 阳性过敏原数为(3.0 ± 1.6)个。最常见的3种吸入性过敏原分别是粉尘螨(904/1 522例, 59%)、户尘螨(891/1 513例, 59%)和链格孢霉(206/1 068例, 19%);最常见的3种食物过敏原分别是虾(251/1 432例, 18%)、鸡蛋白(165/992例, 17%)和牛奶(149/994例, 15%)。3 051例中, 25例(1%)年龄< 2岁, 571例(19%)2 ～ 12岁, 285例(9%)12 ～ 18岁, 2 170例(71%) > 18岁。在< 2岁、2 ～ 12岁患者组中, 最...     

Contact dermatitis with negative patch tests: the additive effect of allergens in combination

We deduced on theoretical grounds that conventional patch testing would be inadequate for the detection of sensitivity to multiple allergens. Fourteen patients with positive patch tests to two unrelated allergens were studied and the response to those two allergens was measured when tested singly or in combination, using 10 different pair combinations from 15 common allergens. With serial dilutions in chloroform (14 patients) and paraffin (four patients), the response was related to the log-dose of the allergen, and change in skin-fold thickness corresponded well with clinical grading. Single allergens diluted below the threshold for a patch-test response gave a response when given in combination, the threshold for a response to one allergen being lowered by the presence of another. On the linear part of the dose-response curves the response to the mixture of allergens was additive, the combined response being the sum of the individual components. Approaching the plateau region the response to the combination was greater than to the individual allergens but less than the sum of the single responses. The same results were obtained with allergens in paraffin. We conclude that conventional single allergen patch testing by itself is inadequate for the diagnosis of contact dermatitis.     

Patch testing with a combination of unrelated allergens: a new strategy

Summary A simplified method of patch testing was designed, in which several totally unrelated allergens were combined in each patch. The method was evaluated by double blind comparison of responses to 17 standard allergens applied individually as 17 conventional patch tests, and as two different sets of five patches each containing combinations of three or four allergens per patch, in 137 patients under investigation for contact allergic dermatitis. There were 89 positive responses to conventional patch testing with separate allergens and 94 and 86 positives to the two different combinations of the same allergens. Concordance of positive reactions to the two combinations was 80% and there were no irritant reactions. Conventional testing detected 70 and 74% of reactions to combination patches 1 and 2 and combination patches 1 and 2 detected 80 and 79% of the reactions to conventional testing. The combinations detected clinically relevant sensitivities not found by conventional testing. Thus, combination patch testing appears to give consistent and reliable results; its use would reduce the number of patches and increase the diagnostic yield for the specialist and permit preliminary screening by the general practitioner.     

用欧洲标准变应原系列检测变应性接触性皮炎

目的　观察欧洲标准变应原系列在我国斑贴试验应用中的可行性。方法　对 181例门诊患者进行了斑贴试验。其中确诊变应性接触性皮炎患者 46例 ,非变应性接触性皮炎患者 2 6例 ,可疑变应性接触性皮炎患者 10 9例。结果　确诊变应性接触性皮炎患者中阳性 45例 ;非变应性接触性皮炎患者阳性 6例 ;斑贴试验的灵敏度为 97.8% ,特异度 76.9% ,准确性 90 .3 % ,阳性预测值 88.2 % ,阴性预测值 95 .2 %。除瘙痒外 ,未见不良反应。可疑变应性接触性皮炎患者结果与以往报告类似。结论　该试剂在我国应用安全有效。